As indicated in Table 1 and clinical trials, multi-target drugs containing an N-benzyl piperazine fragment have shown enhanced efficacy in mitigating cognitive decline and addressing key Alzheimer’s disease pathologies, including amyloid and tau accumulation. This evidence concerns the gene MAPT and Alzheimer disease.